Mining the Genome with Dr. Bruce Korf

How do we integrate genetic and genomic test results into the context of healthcare?

Historically speaking, Electronic Health Records (EHRs) were not designed to be a landing place for genetic and genomic information, but now that such testing is becoming a prominent part of health care and research, the resulting data must have an effective, reliable presence in EHRs. A team at UAB is addressing this need and Dr. Bruce Korf, director of CCTS Genomic Medicine, shares how.

The EHR Challenge

Genomic medicine involves the use of genomic information to guide medical care, but current electronic health records were not designed to incorporate genomic data.  As a result, genomic data, whether obtained through clinical testing or through participation in a research program that returns results to participants, such as AGHI or eMERGE, do not have a standard “home” in the EHR.  This could mean a provider may miss the fact that a test has already been conducted by a research team or another provider, and therefore duplicate testing or fail to take account of test results in providing care. Additionally, one genetic testing outfitter may deliver providers results using electronic web portals and others with paper or pdf reports, making the location of results even trickier.

A streamlined process and designated location for results is now becoming a reality at the CCTS Hub, UAB. Within the next year, UAB’s EHR System, IMPACT (Improved Methods of Patient Information Access of Core Clinical Tasks), will include new areas designated for reports specific to genomic sequencing, pharmacogenetic tests, polygenic risk score results and individual single gene or panel- based test results. Ultimately, it is planned to make it possible for providers to order genomic tests directly from IMPACT, and to arrange for pre- and post-test genetic counseling if desired. 

Dr. Korf, along with a team that includes Nita Limdi, PharmD, PhD, MSPH, FAHA, Associate Director at the UAB Hugh Kaul Personalized Medicine Institute and Principal Investigator for eMERGE, Renie Moss, Program Director for AGHI and Thalia Baker, FACMPE, Associate Vice President of Primary Care at UAB, are working together to examine both clinical and research workflows to ensure successful implementation of IMPACT’s new addition. As the updates begin to roll out, the team will lead a coordinated effort of outreach and education. The CCTS will continue to provide updates on the progress of this exciting project, but if you have specific questions related to genomic medicine and IMPACT, This email address is being protected from spambots. You need JavaScript enabled to view it..

Mining the Genome - Issue 7/ How Genomic Medicine is Answering Big Questions

This schema helps identify the major questions and specific research projects that aim to address the questions. Use it to identify gaps that need to be filled and current studies that aim to help fill these gaps. The list is undoubtedly incomplete, so please also feel free to add both questions and studies that we may have overlooked.

Opportunities  Study
Genome Sequencing
  • Diagnostic Yield
  • Return of Results
  • Resolution of VUS
  Undiagnosed Diseases Program
Population Genomics
  • Engagement 
  • Recruitment
  • Return of Results
  • Outcomes
  Alabama Genomic Health Initiative (AGHI) 
  All of Us
Primary Care Genomics
  • Actionable Variants
  • Pharmacogenetics
  • Polygenic Risk Scores
  • Students
  • Postdocs
  • Primary Physicians
  T32 Genomic Medicine

Below are the research questions being addressed by the CCTS genomics projects underway.

Genome Sequencing
Diagnostic Yield:
• How do you decide who to sequence?
• What is the likelihood that a genome sequencing study is going to be helpful to establish a diagnosis?
• What are the technologies available to increase the probability of success in sequencing, and how do you determine what expectations to set for the given individual?
Return of Results:
• How do you communicate with the patient and family once the genomic sequencing results come in?
• How do educate the patient and family about any findings?
• How do you integrate results into the context of care?
• How do you address the implications for family members?
Resolution of a variant of unknown significance (VUS):
• How do you find out if the VUS is causal to the patient’s symptoms?
• How can data sharing help to resolve VUSs?
• What role does creation of model systems play in resolution of VUSs?

The CCTS Genomics Projects that are taking on these questions:
Undiagnosed Diseases Program, BabySeq, SouthSeq, CPAM

Population Genomics
• How do you earn people’s trust and address their concerns to make sure they are comfortable with the research process?
• What kinds of concerns are important for people of diverse backgrounds?
• How do you recruit in a way that makes signing up and participation easy for all people?
Return of Results:
• How do you return the results in a practical and ethically appropriate way?
• How do you monitor outcomes? What does a person do with the genomic information yielded?

The CCTS Genomics Projects that are taking on these questions:
AHGI, All of Us

Primary Care Genomics
Actionable Variants:
• How do you integrate genomics into the point of care for persons with an actionable variant? (Actionable variants are fairly rare, affecting only between 1 and 3 percent of people, but identifying and treating can produce a significant positive impact on their care.)
• What information might help adjust a patient’s medication regimen?
• Are there adverse effects that can be avoided if you know in advance that a patient is at risk?
• How do you get medication information to the primary physician and guide them in their use?
Polygenic Risk Scores:
• Can you use genomics to come up with a profile of persopnalized risk of common disease and provide a management scheme to deal with that risk?

The CCTS Genomics Projects that are taking on these questions:

• How do we train people (at all levels) in genomic medicine?
• How do you integrate genomics with medical care?

The CCTS Genomics Projects that are taking on these questions:
SURE-GM, T32 in Genomic Medicine, AGHI, BabySeq/SouthSeq

Interested in any of the projects and/or research questions above? This email address is being protected from spambots. You need JavaScript enabled to view it. to connect with Dr. Korf.


Mining the Genome - Issue 6 / UAB Center for Precision Animal Modeling

The UAB Center for Precision Animal Modeling (CPAM) is one of only three centers in the United States funded by the NIH to create animal models for studying disease. The CPAM is still in its first year of its award, and the outreach for projects and collaborators is ramping up. Could the CPAM team and its capabilities have a place in your research? 

While the discovery of a genetic variant may lead to an answer for a patient, genetic variants are oftentimes found to be ‘new’, not yet documented in anyone. Though the variant may seem like a plausible candidate to explain the symptoms a patient is experiencing, these variants of unknown significance (VUS) require functional data to provide certainty. Enter precision animal modeling, putting the variants that are discovered in people into various animal model systems to replicate the phenotype in the model. CCTS Genomic Medicine director Dr. Bruce Korf simplifies the concept further: “If we put this variant or mutation in a mouse, does the mouse express symptoms similar to those in the patient?”

While the physiology of animals is obviously different from that of humans, some of the core features can be replicated, providing confidence that the effect of the variant is relevant to mechanisms of disease pathogenesis. From there, potential therapeutics might be administered, making the modeling process a roadmap to treatments. The animal models may therefore be the frontline before clinical trials. One of the first projects the Center began working on was in partnership with the Wolverine Foundation, a nonprofit searching for treatments for the neuro-developmental disease caused by genetic variations in the gene MAPK8IP3. C. elegans (worm) models can be generated very quickly, so the Center got to work and is now testing repurposed FDA-approved drugs hoping to correct the phenotype. 

Precise Project Selection

So far, forty proposals have been submitted to the CPAM for modeling consideration, with 12-18 projects moving forward through the pipeline currently. Selections are made by a transdisciplinary team of clinicians, cell biologists, and bioinformaticians, along with CPAM leaders Brad Yoder, Ph.D., chair of the UAB Department of Cell, Developmental and Integrative Biology, and Matt Might, Ph.D., director of the Hugh Kaul Precision Medicine Institute. The committee together determines if animal modeling is warranted for the proposal at hand and if so, which animal(s) should be considered, as each offers specific benefits. “We don’t work as silos like we used to. We lean on expertise from wide breadth of disciplines so that we get feedback from all different angles, and that process is exciting and fun,” shares Dr. Yoder. 

Though the selection process is rigorous, Dr. Might highlights the importance of making engagement with the CPAM accessible and valuable, saying, “The CPAM lowers the barrier to entry for clinicians and/or investigators that want to engage in precision disease modeling. In principle, a physician can approach the CPAM with no more than a genetic report and medical history and end up with a model that could either help resolve a diagnostic odyssey or become a platform for further investigation into the disease.”

The CCTS & the CPAM: Pursuing Partnership

There are multiple ways to engage and work with the CPAM. Physicians across the CCTS Partner Network are encouraged to refer patients with chronic, undiagnosed medical conditions for consideration by the Undiagnosed Diseases Program, which serves as a portal to CPAM. Similarly, CCTS investigators can play a vital role in advocating for the priority development of select animal models and/or leverage such models to collaborate in mechanistic studies to help illuminate the biologic impact of genetic variants. Dr. Yoder shares, “We are excited to have models generated in partnership with members of the CCTS, to work together on new models and make them the most useful they can possibly be, but also to utilize the expertise of investigative teams across the Partner Network to thoroughly analyze existing models for further discovery.” 

Learn more about the CPAM and submit a request for the generation of an animal model here or contact This email address is being protected from spambots. You need JavaScript enabled to view it. directly with questions.

Mining the Genome - Issue 5 / Undiagnosed Diseases Program (UDP)

The Undiagnosed Diseases Program (UDP) is a clinical program that launched at the University of Alabama at Birmingham in 2013. The program is funded by institutional support and revenue generated from patient visits. The UDP aims to discover a diagnosis for patients with rare conditions or unusual presentations of not-so-rare conditions, and in the process, to advance medical knowledge about disease. The UDP team has been successful in assigning a diagnosis to 42% of the patients they’ve evaluated thus far.

The Team

Dr. Bruce Korf, director of CCTS Genomic Medicine and medical geneticist in the UAB Department of Genetics is joined by Dr. Anna C. E. Hurst, medical geneticist and pediatrician in the UAB Department of Genetics and Dr. Martin Rodriquez, internist and infectious disease specialist in the UAB Department of Medicine. The team also includes nurse practitioners Kaitlin Callaway and Tammi Skelton. In addition, physicians from various medical specialties provide their expertise on an as-needed basis.

The Process

UDP Quick FactsThe program operates on referrals from providers across the CCTS Partner Network and beyond with guidelines designed to ensure patients have already exhausted all relevant evaluation options. “We consider each referral carefully, asking ourselves if we can add something that might lead to a diagnosis that up until now has escaped detection,” shares Korf. Patients accepted into the program have been experiencing their symptoms for more than 6 months and have already been extensively evaluated without diagnosis. Once a patient enters the UDP, the first step of the process requires careful assembly of what is usually years, and sometimes decades, of medical records and test results. Nurse practitioners Callaway and Skelton prepare a synopsis of the information, and from there, the entire UDP team gathers to discuss their ideas on what the diagnosis may be. This conversation alone may yield a diagnosis, but oftentimes the team turns to genome sequencing, what Korf calls the single most productive tool at hand. It is also quite convenient for Alabama patients, who are able to receive free sequencing provided by CCTS Partner HudsonAlpha Institute for Biotechnology through the Alabama Genomic Health Initiative. Patients in other states are often able to leverage their health insurance coverage.

The sequencing often reveals a genetic variant that contains some of the answers patients and their families have been searching for. Then the UDP team looks for more data, often making use of Gene Matcher, an international database that allows providers all over the world to connect and compare notes over their patients’ common symptoms and genetic variants. “Very often you will find that you’ve got a patient that’s very similar to somebody else’s and they share the same or very similar genetic change and that gives you confidence that the genetic change is the underlying cause of the condition,” shares Korf. From there, treatment options can be explored and medical knowledge can be captured. And sometimes, Korf notes, that knowledge is entirely new: “A handful of cases have even resulted in a new discovery, finding a diagnosis that had never been previously described before but turns out to be a new entity that this patient helps to define.” Now, with the UAB Center for Precision Animal Modeling (CPAM), we have the option of generating model systems to further validate new genomic variants and fuel additional discoveries that may be translated to better care of patients who were previously viewed as medical mysteries.

Learn more about the UDP referral process and submit a referral form here.

Mining the Genome - Issue 4 / Electronic Medical Records and Genomics (eMERGE)

The CCTS sat down with Nita Limdi, Pharm.D, PhD, MSPH, FAHA, professor of neurology and epidemiology, director for the program in Translational Pharmacogenomics, associate director at the UAB Hugh Kaul Personalized Medicine Institute, and principal investigator for eMERGE at UAB, to chat about the plans her team has for the recent eMERGE award they secured last year. Here’s an overview of the goals of eMERGE and what its researchers hope to achieve.  

The History of eMERGE

The Electronic Medical Records and Genomics (eMERGE) consortium was launched by the NIH in September of 2007 with the goal of developing, disseminating, and applying approaches to research that combine biorepositories and electronic medical record (EMR) systems for genomic discovery and implementation research. In addition, the consortium reviews ethical issues like privacy and confidentiality and brings together researchers with a wide range of expertise in genomics, statistics, ethics, informatics and clinical medicine.

The Goals of the eMERGE Network

  • Calculate validated polygenic risk scores (PRS) for comples diseases, telling you how a person's risk for disease compares to others with a different genetic constitution
  • Communicate genomic risk profiles and relevant clinical recommendations based on polygenic risk score (PRS), family history, and other clinical data
  • Recruit and genotype 25,000 individuals of diverse ancestry, prospectively calculate their genomic risk for selected conditions and return risk estimates and management recommendations to participants and providers
  • Assess uptake of risk-reduction recommendation and impact on related clinical outcomes

Take a deeper look at the aims and goals of the eMERGE Network here.

What Are Genomic Risk Scores?

Every individual carries thousands of genetic variations – typically single letter DNA changes.

For some diseases, (e.g. cystic fibrosis) variation in a single gene (e.g. cystic fibrosis transmembrane conductance regulator; CFTR) confers very high risk of getting a particular disease. However, these monogenic diseases are rare. For most common diseases (e.g. coronary heart disease), variation in many genes each conferring a small risk contributes to the risk of developing disease. Researchers identified these many risk variants (using genome wide association studies) and calculated the overall risk score based on the sum of all the common variants. These polygenic risk scores (PRS), when combined with lifestyle and clinical factors, provide a comprehensive Genome Informed Risk Assessment (GIRA). The PRS can help estimate future risk of common diseases (e.g. heart disease, diabetes, hypertension etc.) and the GIRA can inform treatment interventions (e.g. additional lab tests, medications, lifestyle changes) to tailor preventive strategies for mitigating the disease risk.

UAB Joined eMERGE in 2020 with the Aim of Integrating Genomic Risk Assessment for Chronic Disease Management in a Diverse Population

In 2020, Dr. Limdi and James Cimino, MD, were awarded eMERGE funding (making UAB the only site added to the eMERGE consortium this round) that would create even more opportunity for discovery in genomic medicine. Limdi knew that the University of Alabama at Birmingham had diverse cohorts for integration into this study, and she designed the grant to explore those diverse populations. The team’s specific aims are to:

  • Select 15 common diseases and race-specific polygenic risk scores (PRS)
  • Explore patient perspectives on use of family history and PRS for estimating disease risk among AGHI participants
  • Establish methods to implement genomic risk assessment and risk management in clinical care
      • To recruit 2,500 patients in general medicine practice with greater than 75% being in underserved populations
      • To incorporate polygenic risk scores, family history, and clinical data to compute genomic risk estimate for 15 common diseases
      • To identify high-risk patients (top 2%) for each disease and deploy risk reduction recommendations
      • To assess the uptake of genomic risk assessments, adherence to clinical visits, and clinical outcomes

What UAB Brings to the Table

“There have been more than 4,000 genome-wide association studies conducted that have enabled the development of polygenic risk scores, which can be used to predict the risk of many common diseases,” shares Limdi. However, Limdi says those risk scores were derived primarily from patients of European or Asian descent and that patients of African descent are dramatically underrepresented by the scores. “Our challenge will be to recruit and collect more data on underrepresented populations and to use that data to better understand how we can employ genomic scores to predict disease risk in people of other races,” Limdi says.

What may also be most significant about the study is the unique comprehensive approach the team is taking to assessing appropriate clinical care. “The vital first step to leverage the power of genomics to prevent disease is to use genomic risk assessments to identify and — where appropriate — pre-treat at-risk patients,” Limdi says. “At UAB, we will bring our expertise and experience to collaborate with the eMERGE investigative team to take this vital first step."

Limdi looks forward to those results. “We’ve used genomics to diagnose disease. We’ve used genomics to treat disease. But now we are using genomics to see if we can truly prevent disease. And I find that very exciting.”

Mining the Genome - Issue 3 / Alabama Genomics Health Initiative (AGHI) Will Begin Enrollment with Clinical Practice Partners

The Alabama Genomics Health Initiative (AGHI) is in its fifth year of providing participants genomic testing to identify genetic variants that predict high risk for diseases like cancer and heart disease and genetic counseling to support early interventions and treatments. The partnership between UAB and HudsonAlpha Institute for Biotechnology also includes a focus on research, through which data from test results from across 67 Alabama counties will be used to advance scientific understanding of the role that genes play in health and disease.

Now the AGHI will be embedded into clinical practice in Birmingham, Hoover, and Selma, Alabama, setting the stage for precision care that is better-informed and more cost-effective. CCTS Genomic Medicine Director and AGHI principal investigator Dr. Bruce Korf shares more about the potential of this pilot opportunity.

The Decision to Move to Clinical Practice

In March, the COVID-19 pandemic paused AGHI enrollment, but even in spite of that, AGHI leadership had been contemplating a change in the enrollment strategy. “When we started AGHI, the All of Us Research Program wasn’t active in our region, and even if it had been, it wasn’t offering anything in genomics at the time,” explains Dr. Korf, who leads the southern network of the All of Us Research Program. Now that fact has changed, and All of Us provides participants the same genetic feedback the AGHI does. So the AGHI team asked themselves, “What can we do that All of Us is not able to do, that would preserve our ability to generate a research database while returning value to our participants?” Integrating into medical practices, working hand in hand with providers, was the answer.

Minimizing Disruption in a Clinical Setting

Adding more responsibility to the plates of physicians treating patients while navigating a pandemic is what the AGHI is trying hard to avoid. Renie Moss, AGHI Program Director, works with the physicians who will be launching this pilot, incorporating the AGHI workflow into practice. “The feedback we have received from the physicians is that they are definitely eager to be able to provide information to their patients that would come from AGHI enrollment, but along with that enthusiasm is the request for more information about how this will work in a busy clinic setting,” shares Ms. Moss. The basic workflow sounds simple: physicians enroll their patients, patients consent to the genotyping, and physicians deliver the results, incorporating those results into the patient’s care where appropriate. But the AGHI team is building the systems that will make the process easier with things like:

  • developing an e-consent and telemedicine enrollment process that minimizes interruption of the actual clinical appointment,

  • creating physician educational resources that can be provided online/virtually, both out of respect for busy practitioners and in response to the pandemic, and 

  • leaning on established experience of the participant recruitment team in the UAB Recruitment and Retention Shared Facility.

Erin Delaney, MD, the Clinical Medical Director at UAB Highlands, will be among the first to implement the new workflow: 
“Our clinic is thrilled to be amongst the first clinics to pilot the integration of AGHI into our practice. We know this will be a learning process for our providers, staff and patients, yet we feel the ultimate benefits, including improved health outcomes, for our community of patients will be long-lasting and certainly worthy of this journey. We are excited about taking the next steps with AGHI to bring this level of medicine to our patients.”

But Wait, There's More

Patients will also have access to pharmacogenetic testing, which provides the genetic underpinnings that can be used to predict their body’s response to certain drugs. Participants who opt-in to pharmacogenetic testing will receive information that could guide which drugs are prescribed to them and at what dosage. Dr. Nita Limdi, Director of the Translational Pharmacogenomics Program and Associate Director of the Hugh Kaul Personalized Medicine Institute, is passionate about the benefit this testing has on both patient health outcomes and financial stewardship. Over $330 billion is spent on medications each year in the United States, and chronic diseases account for 90% of our healthcare expenses. Money is wasted when a drug doesn’t work. Previous trial-and-error approaches in prescribing medications were often met by poor efficacy in large fractions of patients. As Dr. Limdi points out, one might imagine how much time and money could be saved through this pharmacogenetic testing, which can predict treatment response in advance. AGHI will further empower physicians with evidence-based support to make treatment decisions, with guidance from Dr. Limdi and her team. “As we bolster relationships with physicians,” explains Limdi, “this effort will serve as a platform to communicate about the utilization of genetic results in precision medicine and to collect feedback on how we may optimize the use of this technology judiciously.”

  • Our department is excited to think about the future of medicine and primary care, particularly in the area of identifying and treating chronic diseases. For successful implementation, it requires new team members who can help clinicians learn, develop, and deliver this exciting tool. We look forward to continuing our work with the Alabama Genomic Health Initiative.

    - Irfan Asif, MD, Chair of the Department of Family and Community, UAB

Mining the Genome - Issue 2 / All of Us Research Program Update

We’re wrapping up November with our second “Mining the Genome” conversation with Dr. Bruce Korf, CCTS Genomic Medicine Director. Over the course of the month, we’ve introduced our members to the newly launched All of Us Researcher Workbench beta, and in this conversation, Dr. Korf helped provide some quick takeaways for utilizing this resource:

  • UAB is the hub of the All of Us Southern Network, strengthened by the CCTS Partner Network, and was one of the largest enrolling sites in the country before the current pandemic.

  • Reactivation efforts are underway, with emphasis on participant retention, including re-consenting participants to utilize the now-available genome sequencing and genotyping.

  • Researchers from institutions with signed Data Use Agreements can begin using the Researcher Workbench.

  • Researchers can create workspaces within the Workbench to create and analyze cohorts of large numbers of de-identified data sets and access genomic data to look for genomic markers.

  • Enrollment in All of Us is still underway, so the data is not yet complete, but will grow richer as participation grows (All of Us aims to engage a cohort of 1 million or more!)

  • UAB has a signed DUA, so any UAB researcher can access the Workbench beta site at this time.

Click here to learn more and access the recent CCTS training and slide deck on the Researcher Workbench beta. You can also explore additional tutorials here.

Mining the Genome - Issue 1 / Introduction to Genomic Medicine

An exceptional amount of genomics research activity is underway both locally and nationally, and this column will share new developments and possible implications that will hopefully result in more opportunities for researchers to connect ideas and efforts. Each month, the CCTS will share a conversation with the director of CCTS Genomic Medicine, Bruce Korf, MD, PhD, Wayne H. and Sara Crews Finley Endowed Chair in Medical Genetics, Associate Dean for Genomic Medicine at UAB, and the Chief Genomics Officer for UAB Medicine. Dr. Korf will be providing updates on an array of genomics-related topics and at the end of each column will provide guidance on how you can connect further on that topic.

Let’s kick off this series by establishing a foundation, some genomics groundwork, courtesy of Dr. Korf.

CCTS: What is the overall goal in genomic medicine, from a ‘big picture’ perspective?

Korf: People have been excited about genomics opportunities since the human genome sequence was deciphered, which was now about 17 years ago. But what has become clear is that having the sequence in hand doesn’t automatically translate into better patient care. There’s a lot that has to be done to take that information and develop the systems needed to apply it to patient care, to validate it and demonstrate that it is effective and safe to use. It has therefore taken a fair amount of time to reach this point, where we are now seeing research that is used in routine practice.

From the perspective of an academic medical center, I think there are two things critical for us to keep in mind. We want to provide the best access to cutting edge care that we can—as genomic medicine-related technologies become available and are demonstrated to be effective, we want to make sure our patients have access. But we must also do the work to demonstrate that these approaches have clinical utility. It isn’t just our job to read the book of genomic medicine and apply it to our patients, but to actually write the book.

CCTS: What is genomic medicine?

Korf: Genomics is the study of the entire human genome, the entire complement of genetic material in each of our cells. We have altogether 6 billion base pair of DNA and these encode some 22,000 genes and all of the regulatory processes that turn those genes on or off in the right time and the right place. Genomics really amounts to studying large collections of genetic elements, both genes and control processes to try and put them together into an understanding of how they are important in regulating cell processes, and ultimately contributing to health and disease.

Genetics, in contrast, usually focuses on one gene at a time, and how it is passed from generation to generation and how it functions in the cell, so with genomics we are looking at genes much more globally or collectively. Metaphorically, think of genetics as a book that describes a complicated cellular process and think of genomics as a library of where all of those books are collected.

The concept of genomic medicine is using genomic information to make decisions to either prevent, diagnose, or treat disease. Some of it happens at a at a population level, trying to identify individuals at risk and using that information to try and prevent them from developing disease. Some of it is in achieving a more precise diagnosis in an individual who has symptoms of disease. And finally, genomics also comes into use to identify and guide treatment, and to be sure that treatments being used are used optimally to maximize benefit and minimize side effects.

What initiatives and research developments will Dr. Korf be sharing over the coming months?

Since the genomics landscape is so vast, Korf organizes genomics research into three arenas: rare diseases, common diseases, and cancer, and then conceptualizes each of those into three parts: prevention, diagnosis, and treatment. Korf will use this columns to talk about that entire ‘matrix’ of the genomics world, including work surrounding:

  • The Undiagnosed Diseases Program, which has a 30% success rate in providing a diagnosis for patients who have had great difficulty in receiving a diagnosis

  • The role of genomics in customized cancer therapies

  • The Alabama Genomic Health Initiative, testing Alabamians for the presence of specific genetic variants that may predict the development of serious medical conditions that can be prevented or treated if the diagnosis is made early

  • The All of Us Research Program, an NIH-sponsored initiative to enroll 1 million people to sequence their genomes and collect electronic health record information

  • The eMERGE Consortium, which has a goal to develop polygenic risk scores to identify people at unusually higher risks of disease and use that to institute effective treatments

  • Advancements in Maternal Fetal Medicine preconception counseling and carrier testing

  • The Hugh Kaul Precision Medicine Institute’s work to understand the underlying cause of disease at a genetic level in order to select therapies

  • Developments in pharmacogenetic testing

  • The Center for Precision Animal Models (C-PAM), which is taking genomic variance and developing various animal models that can be used to further study how those gene variants influence disease and treatment.